— Know what they know.
Not Investment Advice
Also trades as: TPVY (NYSE) · $vol 0M

TPVG NYSE

TriplePoint Venture Growth BDC Corp.
1W: -2.6% 1M: -3.0% 3M: -10.9% YTD: -31.3% 1Y: -31.4% 3Y: -44.3% 5Y: -46.5%
$4.56
+0.07 (+1.45%)
 
Weekly Expected Move ±5.2%
$4 $4 $4 $5 $5
NYSE · Financial Services · Asset Management · Alpha Radar Strong Sell · Power 29 · $185.1M mcap · 38M float · 0.765% daily turnover · Short 60% of daily vol
Smart Money Score
Watch 0
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$185.1M
52W Range4.395-7.21
Volume284,945
Avg Volume290,598
Beta1.34
Dividend$0.94
Analyst Ratings
1 Buy 10 Hold 1 Sell
Consensus Hold
Company Info
CEOJames Peter Labe
SectorFinancial Services
IndustryAsset Management
IPO Date2014-03-06
Websitetpvg.com
2755 Sand Hill Road
Menlo Park, CA 94025
US
650-854-2090
About TriplePoint Venture Growth BDC Corp.

TriplePoint Venture Growth BDC Corp. (TPVG) functions as a business development company, primarily concentrating its investments on growth-stage enterprises backed by venture capital. The firm's core offering involves providing debt financing solutions to companies within the venture growth ecosystem. These solutions encompass a diverse range of products, such as growth capital loans, customized and secured credit facilities, equipment financing, and revolving lines of credit. Additionally, TPVG engages in direct equity investments. Its investment strategy targets companies operating in key sectors, including e-commerce, entertainment, technology, and life sciences. Within the technology sphere, the areas of specific interest are broad, covering cybersecurity, wireless communication equipment, network systems and software, business application software, conferencing solutions, big data analytics, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, various software categories (including Software-as-a-Service), and other related technological subsectors. For life sciences, TPVG focuses on biotechnology, biofuels/biomass, diagnostic testing and bioinformatics, drug delivery systems, drug discovery, healthcare information systems, healthcare services, medical/surgical/therapeutic devices, pharmaceuticals, and other related fields. The size of TPVG's investments varies based on the type of financing: growth capital loans typically range from $5 million to $50 million, equipment financings are between $5 million and $25 million, and revolving loans generally fall between $1 million and $25 million. Direct equity investments, conversely, are usually from $0.1 million to $5 million, and are structured to not exceed 5% of the portfolio company's total equity. The debt financing instruments are commonly structured as lines of credit, and the company also employs warrants and secured loans in its funding approach. TPVG aims to achieve targeted returns of 10% to 18%. A distinctive aspect of its investment policy is that it does not seek board representation in the companies it finances.

Recent Insider Trades

NameTypeSharesPriceDate
Labe James P-Purchase 23,799 $6.66 2026-01-12
Srivastava Sajal P-Purchase 23,799 $6.66 2026-01-12
Labe James P-Purchase 16,000 $6.56 2026-01-09
Srivastava Sajal P-Purchase 16,000 $6.56 2026-01-09
Srivastava Sajal P-Purchase 16,833 $6.61 2026-01-08

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms